Purple Biotech (PPBT) Payables (2014 - 2026)
Purple Biotech (PPBT) posted quarterly Payables of $843000.0 for Q1 2026, down 2.88% year-over-year from $868000.0 in Q1 2025, and down 59.28% quarter-over-quarter from $2.1 million in Q4 2025.
Purple Biotech (PPBT) Payables (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Payables for 13 consecutive years, with $843000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables fell 2.88% year-over-year to $843000.0; the TTM figure through Mar 2026 stood at $843000.0 (down 2.88% YoY), while the FY2025 annual figure was $2.1 million, up 42.27% from the prior year.
- Payables slipped to $843000.0 in Q1 2026 per PPBT's latest filing, from $2.1 million in the prior quarter.
- Across five years, Payables topped out at $3.5 million in Q4 2023 and bottomed at $605000.0 in Q3 2025.
- Historically, Payables has averaged $1.9 million across 5 years, with a median of $1.9 million in 2024.
- Annual changes were most pronounced in 2024 — Payables soared 93.51% — and 2025, when it sank 78.01%.
- Purple Biotech's Payables stood at $2.1 million in 2022, then jumped by 65.67% to $3.5 million in 2023, then plunged by 58.81% to $1.5 million in 2024, then soared by 42.27% to $2.1 million in 2025, then slumped by 59.28% to $843000.0 in 2026.
- Business Quant data shows PPBT's Payables at $843000.0 in Q1 2026, $2.1 million in Q4 2025, and $605000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.69 Bn | 130.84 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.29 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.79 Bn | 59.60 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 59.44 Bn | 54.31 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.92 Bn | 27.61 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.10 Bn | 9.71 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.33 Bn | 26.17 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 35.57 Mn |
| 10 | Purple Biotech | 127.07 | 127.07 | - | 487,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 843,000.00 |
| Dec 31, 2025 | 2.07 Mn |
| Sep 30, 2025 | 605,000.00 |
| Jun 30, 2025 | 669,000.00 |
| Mar 31, 2025 | 868,000.00 |
| Dec 31, 2024 | 1.46 Mn |
| Sep 30, 2024 | 1.91 Mn |
| Jun 30, 2024 | 3.04 Mn |
| Mar 31, 2024 | 3.48 Mn |
| Dec 31, 2023 | 3.53 Mn |
| Sep 30, 2023 | 2.59 Mn |
| Jun 30, 2023 | 1.57 Mn |
| Mar 31, 2023 | 2.45 Mn |
| Dec 31, 2022 | 2.13 Mn |
| Sep 30, 2022 | 2.77 Mn |
| Jun 30, 2022 | 1.23 Mn |
| Mar 31, 2022 | 1.65 Mn |
| Dec 31, 2021 | 1.47 Mn |
| Sep 30, 2021 | 2.08 Mn |
| Jun 30, 2021 | 2.07 Mn |